Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on October 21, 2019. The report discloses the resignation of a senior executive and the terms of a subsequent separation and consulting agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the compensation package for the departing executive:
- Consulting Compensation (Nov 1, 2019 - Dec 31, 2019): $10,000 per month.
- Consulting Compensation (Jan 1, 2020 - Feb 29, 2020): $5,000 per month.
- Equity: Continued vesting of outstanding equity awards during the agreement term.
- Expenses: Reimbursement for certain consulting-related expenses.
Material Changes
The primary material change is the departure of Mina Kim, Senior Vice President, Corporate Strategy and General Counsel, effective November 1, 2019. This is followed by a transition period where she will serve as a consultant until April 10, 2020.
Outlook, Risks, and Management Commentary
Management has entered into a separation agreement to ensure a smooth transition of duties. The agreement includes a general release and waiver of claims by Ms. Kim. The full text of the agreement is referenced as an exhibit to the Company's annual report on Form 10-K for the year ending December 31, 2019. No specific business outlook or new risk factors were disclosed in this filing.
Key Facts for Investor Verification
- Confirm the effective date of Mina Kim's resignation (November 1, 2019).
- Verify the total potential consulting fees ($10,000/month for two months and $5,000/month for two months).
- Review the upcoming Form 10-K for the full text of the separation and consulting agreement.
- Monitor for announcements regarding the appointment of a replacement for the General Counsel role.